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278 However, often SVs that are suspected, perhaps due to rarity and size, to causally underlie the shared phenotype of a group of patients do not physically overlap but are instead distributed across the genome. In such cases, functional enrichment analysis (FEA) approaches that make use of distinct but dispersed candidate loci may be employed [Curtis et al., 2005; Nguyen et al., 2006 Nguyen et al., , 2008 Huang da et al., 2009] . The biological hypothesis explored by FEA is that there is some property that is more common among these loci than might be expected by chance, and that the shared property among these loci is causally related to the cohort's shared phenotypic characteristics ( fig. 1 B) .
To facilitate the application of FEA, a plethora of webbased services have been set up [Huang da et al., 2009] . With these services, users can readily identify over-represented functional characteristics within a set of loci [see Huang da et al., 2009 , for a systematic overview of these services]. Providing readily accessible FEA tools to nontechnical users has enabled a large number of novel findings. Many of these services provide the clinical geneticist with a 'one-stop shop' for the analysis of their data, including graphical representations to assist the interpretation and publication of findings. The development of such services is to be lauded, particularly as funding models for their maintenance is currently lacking. Despite their number, the many applications of FEA cannot all be explicitly catered for by these services and FEA must always be applied with the thought and consideration due to any scientific experiment. This is particularly true for the analysis of SVs, as many of these FEA services have been developed to aid the analysis of differ- Strategies for associating structural variation with patient phenotypes. A Several overlapping structural variants that cumulatively define a critical genomic region that may be associated with the common patient phenotype. B Structural variants identified at dispersed loci within a cohort with a common phenotype may each disrupt different functional elements that participate in the same pathway/process. The disruption of a common pathway/process may explain the shared symptoms within the cohort.
ential expression experiments rather than SVs [Huang da et al., 2009] .
The purpose of this brief review is to identify those aspects of FEA that need to be considered carefully when applying FEA to SVs. As we illustrate below, the key to testing these types of hypotheses lies in defining what is significantly unusual and in understanding how best to exploit the functional genomics resources employed to define the genic properties examined.
Choosing and Testing the Null Hypothesis
Enrichment is defined as a quantity that is observed in excess of some expected level, while the statistical significance of an enrichment describes how often an enrichment of the same magnitude is expected just by chance alone. How the expected quantity is defined is clearly fundamental to the result and thus needs to be chosen, and examined, with appropriate care. Generally, the statistical test that is employed to compare observed to expected numbers and determine the significance of any difference is based around the hypergeometric distribution, which describes the likelihood of sampling from a population without replacement. As biological functions are most often accorded to loci by considering the protein-coding genes they harbour (see below), the test is most often constructed to report the chance of finding the observed number of genes associated with a particular function among the total set of genes at these loci, given the proportion of genes with that particular function within the genome as a whole or within a control population.
In order to make the statistics simple, overlapping SVs are often merged such that any gene may be sampled only once by each of the case and control variant sets. The numbers of genes that possess and do not possess a particular functional annotation in each of the case and control gene sets are then compared within a contingency table, and a Fisher's exact or a 2 test is performed to ascertain significance. Importantly, the p values obtained by testing many different genic annotation terms need to be adjusted for the increased likelihood of a false positive arising by chance due to the many tests performed. To perform this correction, the straightforward but punitive Bonferroni correction has now given way to the less conservative false discovery rate (FDR) [Benjamini and Hochberg, 1995; Storey, 2002] .
The choice of an appropriate expectation is fundamental to the result. Where possible, the background distribution should be chosen to accurately reflect potential biases in the set of SVs of interest that may affect this expectation. Ideally, the background would be best constituted by an equivalent set of SVs identified in a case-consistent way among a matched control cohort. This control set of variants reflects the uneven occurrence of structural variation, and therefore the uneven sampling of genes, across the genome [Cooper et al., 2007; Nguyen et al., 2006 Nguyen et al., , 2008 Redon et al., 2006] . Where an appropriately matched set of control SVs has not been collected, generalised control sets have been made available for comparison [Nguyen et al., 2008; Shaikh et al., 2009] .
Appropriate control sets may not be available for some types of SVs. For example, it would be inappropriate to compare a set of de novo SVs identified in a particular patient cohort with a set of largely inherited SVs, as selective pressures are likely to have significantly culled the SVs observed in the latter [Cooper et al., 2007; Nguyen et al., 2008; Raychaudhuri et al., 2010] . In such cases, it is better to compare the set of affected genes to the total population of genes using a hypergeometric test [Webber et al., 2009; Shaikh et al., 2011] . However, if the hypothesis being considered is that the deleterious effects of the de novo SVs are highly penetrant, then it is reasonable to remove from the set of affected genes those genes that have also been observed to be copy number variable among apparently healthy individuals [Webber et al., 2009; Shaikh et al., 2011] .
The approaches described above count each gene only once and thus gain no additional power from recurrently affected loci. Given a set of appropriately matched controls, an alternative approach is to compare the frequencies of individuals within the case and control populations who possess SVs that affect genes with a particular functional annotation [Raychaudhuri et al., 2010] . As each individual is counted only once, this approach avoids over-weighting those members of a cohort with variants that overlap a cluster of genes that share a common functional annotation. Given the many paralogous clusters of genes within the genome, such occurrences are not uncommon and reduce the generality and utility of an identified enrichment they contribute to. Indeed, SVs are more likely to arise in genomic regions that harbour paralogous clusters of genes [Cooper et al., 2007; Nguyen et al., 2006 Nguyen et al., , 2008 . However, care must be taken when down-weighting the contribution of the simultaneous change in copy number of paralogues as such cases can be more deleterious than their individual change due to the loss of functional redundancy [Petryniak et al., 2007] .
Irrespective of the approach, it is important to examine the expectation under the null hypothesis to ensure that there are no artefactual biases. To examine the null, a set of randomly obtained p values can be obtained. The demonstration that the null is well behaved is a reasonable requirement of any FEA. Generally, the null should provide a uniform distribution of p values for any given annotation term ( fig. 2 ) . While sparsely annotated terms may yield an over-representation of high p values ( fig. 2 B) , a bias towards an enrichment of low p values can indicate a concerning high likelihood of false-positive results ( fig. 2 A) . Where a case/control comparison has been performed, a distribution of randomised p values can be generated by repeated case/control label permutation and re-testing for genic annotation enrichment. Where a case/control comparison has not been employed, randomly generated sets of genomic regions matched in size and number to the observed set of SVs can be used to generate a suitable null distribution. Given the known G + C biases associated with the occurrence of genes and structural variation, it might be wise to retain the G + C content of the set of observed SVs within the randomised sets [Nguyen et al., 2008] . Although holding the G + C content constant within the randomised sets may not affect the functional content of the genes overlapped, it is likely that the randomised sets will possess a lower G + C content than the observed set of SVs and therefore overlap fewer genes. A significant reduction in the number of genes could lead to a larger variance in the distribution of enrichments found under the null.
Gene Assignment and Functional Bias
The process used to determine those genes affected by a set of SVs, and therefore the set of genes upon which the enrichment analysis will be performed, is a common cause of substantial experimental bias [Raychaudhuri et shown is formed from 500 randomisations. Each randomisation obtained a set of genomic intervals matched in size and number to those de novo copy number variants identified in individuals with autism in a recent Autism Genome Project publication [Pinto et al., 2010] . For each set of random genomic intervals, overlapped genes were formed into a gene set, and the number of genes within this set, whose unique mouse orthologue yields a nervous system phenotype when disrupted, was found. The likelihood of obtaining this number of nervous system-associated genes was then determined using a hypergeometric test. How the genes were assigned to the randomly obtained intervals varies: in A , all genes overlapped in any manner by an interval were taken to form each gene set; in B only genes that reside wholly within an interval were taken to form each gene set; in C only those genes where the randomly obtained interval overlaps at least one coding exon in every known transcript of that gene were taken to form each gene set.
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Cytogenet Genome Res 2011;135:277-285 281 al., 2010]. The cause of this bias lies in the observation that there are significant differences in the lengths of genes whose expression is specific to certain tissues ( fig. 3 ). Thus, great care is required if the disorder being studied is likely to involve genes with a particular tissuespecific expression pattern. Amongst all the tissues, the cause for greatest concern with respect to length biases are those genes specifically expressed in the brain. Brain-specific genes, defined here as those genes whose expression is more than 4 times higher in the brain compared to their median expression level across all other tissues, are on average 44% longer than the other genes (medians 37.1 vs. 25.8 kb, respectively, Mann-Whitney U test p = 8 ! 10 -4 ; fig. 3 ). Thus, the likelihood of a brain-specific gene being overlapped by a randomly chosen interval is higher than that for genes expressed elsewhere creating an increased chance of false-positive enrichments [Raychaudhuri et al., 2010] . The effect of this bias can be observed in the significant increase in the frequency of low p value enrichments of genes that are associated with nervous system phenotypes overlapped by randomly drawn genomic segments ( fig. 2 A) . By contrast, genes expressed specifically in the heart are on average smaller and therefore less likely to be sampled by a random genomic segment ( fig. 3 ). These biases illustrate the importance of examining the expectations under the null.
The criteria used to determine if a gene is affected by an SV can have a profound effect on how tissue-specific gene length biases manifest within the FEA experiments. Due to the concern that the boundaries of SVs detected by earlier array platforms might be over-estimated, some experimentalists record a gene as affected by an SV only if the entire gene is overlapped by the variant [Webber et al., 2009; Shaikh et al., 2011] . As fewer long genes can wholly reside within a given interval than shorter genes, and as longer genes are more likely a priori to overlap the boundary of an interval, taking only those genes completely overlapped by an SV will penalise longer genes. The effect of this is observed in the increased frequency of high p value enrichments of genes that are associated with nervous system phenotypes overlapped by randomly drawn genomic segments ( fig. 2 B) . Thus, taking only completely overlapped genes forms a conservative FEA approach, more likely to yield false negatives when, for example, considering disorders of the nervous system that are likely to involve long brain-specific genes.
Technological improvements in our ability to resolve genomic structural variation have enabled the reliable detection of increasingly smaller SVs. Consequently, we are Variation in gene length and protein-coding length between genes specifically expressed in particular tissues. Gene groups are labelled as follows: All: all genes; Br-e: brain-expressed genes defined as an expression level of 100 or greater in brain tissue; Br-s: genes with brain-specific expression; Ht-sp: genes with heart-specific expression; Lv-sp: genes with liver-specific expression; Pn-s: genes with pancreas-specific expression; Wb-s: genes with whole blood-specific expression; Kd-s: genes with kidney-specific expression; Te-s: genes with testes-specific expression; SM-s: genes with skeletal muscle-specific expression. Tissue-specific expression is defined as those genes that exhibit an expression level in a stated tissue that is greater than 4 times the median level observed across other tissues [Webber et al., 2009 ].
Webber Cytogenet Genome Res 2011; 135:277-285 282 identifying variants that, despite initially appearing disruptive to a gene, on closer inspection lie wholly within a single intron [Pinto et al., 2010] . Entirely intronic variants may still exert pathogenic effects by disrupting splicing or regulatory elements, but these effects are usually much more difficult to quantify by computational sequence analysis alone. In addition, a variant that disrupts coding exons that are only expressed in a subset of transcripts may yield potentially diminished deleterious consequences compared to a variant that knocks out the whole gene. Thus, it may be more robust to consider only those genes where an SV disrupts at least one coding exon in every known transcript of that gene. While this gene selection approach is still subject to biases such as proteincoding length variation ( fig. 3 ) , intron number and length differences between genes expressed specifically in different tissues [Sironi et al., 2005; Vinogradov, 2006] , the resulting biases within the null distribution are demonstrably diminished ( fig. 2 C) .
Sources of Functional Gene Information
The power to detect enrichments of function within loci affected by SVs is limited by the availability of functional annotations. As protein-coding genes have been the focus of the vast majority of functional studies, human functional genetic information is largely available only for protein-coding genes [Hubbard et al., 2009] . Thus, despite clear roles for other types of genetic elements such as regulatory elements and non-protein coding RNAs, FEA is generally currently limited to considering annotations associated with protein-coding genes.
Commonly used sources of functional information include literature annotations (e.g. Gene Ontology [Harris et al., 2004; The Gene Ontology Consortium et al., 2000] , KEGG [Kanehisa et al., 2008] , REACTOME [Croft et al., 2011] , gene expression and co-expression [Stuart et al., 2003; Su et al., 2004] , sequence classification (e.g. PFAM [Finn et al., 2010] , INTERPRO [Hunter et al., 2009] ) and interaction information (e.g. MIPS [Mewes et al., 2011] , STRING [von Mering et al., 2003] ). Each of these sources of genic information requires careful consideration in their use and each has been the subject of several reviews [von Mering et al., 2002; Sprinzak et al., 2003; Royce et al., 2005; Verducci et al., 2006; Rhee et al., 2008; Zhang et al., 2009] .
By far the most commonly employed resource for FEA are Gene Ontology (GO) annotations [Harris et al., 2004; The Gene Ontology Consortium et al., 2000] . In order to exploit the wealth of literature-reported studies into gene function through computational methods, the findings of these studies must be defined using a consistent and common language. For this purpose, the GO consortium employs 3 distinct ontologies, each with a controlled and structured vocabulary, that describe the molecular functions, cellular locations or the biological processes of a gene and its products, respectively [The Gene Ontology Consortium et al., 2000] . By interpreting reported information associated with genes into a consistent language, GO has enabled the ready comparison of the knowledge associated with products of different genes and thus the detection of shared functionality.
The GO consortium exploits many different sources of information to assign GO terms to a gene/product, and these sources vary in their reliability. For example, at the time of writing, of 218,227 GO terms associated with human genes within ENSEMBL (Mart 62) [Hubbard et al., 2009] , there is direct experimental evidence for only 44,018 (20%) of these assignments. The remainder are assigned without expert curation, most often through computational prediction. As the prediction of highly specific GO terms is prone to error, an initial strategy might be to examine only broad, high-level annotations for enrichments. The GO consortium provides a reduced set of 106 broad terms, named GO Slim , that may be used for this purpose [Harris et al., 2004] . Furthermore, examining only the terms described within the GO Slim set reduces the required multiple testing correction (see above) as compared to searching all 11,284 GO terms currently assigned to human genes. Indeed, when considering any genic annotation term, it is sensible to only consider those terms which are shared amongst a reasonable number of genes. Removing rare terms avoids unnecessary tests that may be unable to reach the threshold of significance and increases the power to identify associations which are more broadly relevant to the disorder. However, despite these and other considerations (for a full discussion see Rhee et al. [2008] ), GO annotations provide an excellent resource for biological discovery.
A long-standing resource that has only recently been exploited in FEA and is of particular relevance to theclinical geneticist considering the effects of SVs are the phenotypes that result from the determined disruption of genes within the mouse [Eppig et al., 2007; Webber et al., 2009] . When considering the effects of SVs causing gene loss, 'knock-out' mice provide arguably the most genotypically relevant experimental results in a medically relevant model organism. While this information is currently available for approximately a quarter of human:mouse 1: 1 orthologues [Eppig et al., 2007] , recent commitments to fund the KOMP2 programme promise to provide broad-scale phenotypic information for more than 10,000 additional gene knock-out phenotypes (http://commonfund.nih.gov/KOMP2). As the mouse phenotype resulting from a gene knock-out can present the effects at the organismal level, these phenotypes are often much more readily comparable to the phenotype of a patient recorded in a clinical setting than other, more molecular, functional annotations of genes. This is particularly true when examining SVs underlying human disorders defined solely by complex behavioural presentations, such as neurodevelopmental or neuropsychiatric disorders, where concepts such as 'face validity' can be meaningfully applied [Chadman et al., 2009; Patterson 2011] . The use of mouse knock-out model phenotypes may be especially appropriate when examining SVs thought to be highly penetrant, as penetrant mutations are thought to more accurately translate into clearly identifiable phenotypes within the mouse [Shahbazian et al., 2002; Gotz and Ittner, 2008; Moy and Nadler, 2008] .
As with GO, the phenotypes resulting from mouse experiments have been formalised into a structured ontology, the Mammalian Phenotype Ontology (MPO) [Smith et al., 2005; Smith and Eppig, 2009] , and this data is readily available from the Mouse Genome Informatics (MGI) resource [Eppig et al., 2007] . Testing each of the 6,944 phenotypic terms that can be associated through orthology to human genes would incur a severe multiple testing correction. Alternatively, a 2-stage strategy may be employed [Webber et al., 2009] . This strategy exploits the organisation of the MPO into 29 over-arching broad phenotypic categories. In the first stage, each of these 29 overarching phenotypes are examined for an enrichment of genes whose mouse orthologue's disruption yields that specific phenotypic category. If any category of phenotypes is found to be significantly enriched, then a second round of analysis may be conducted in which each specific term within those enriched phenotypic categories are considered in turn. A weaker, hypothesis-led, approach might be to circumvent the first stage by selecting those phenotypic categories likely to be most relevant to the disease of interest [Shaikh et al., 2011] .
As with all functional genomics resources, some consideration is required to best exploit the mouse phenotypic resources. Firstly, the vast majority of mouse models recorded within the MGI have not been systematically phenotyped but rather examined with specific hypotheses in mind. While the lack of complete and consistent examination of a gene's properties is a common problem among literature-derived resources, it is especially true of the mouse phenotypic resource due to the investment required to determine each individual phenotype for every gene. Thus, when the necessary assumption is made that a gene's disruption does not yield a particular phenotype because that phenotype is not reported, it ought to be expected that there will be many false negatives. The proposed KOMP2 phenotyping project will in part address this by carrying out systematic phenotyping, although necessarily only for a limited number of phenotypes [http://commonfund.nih.gov/pdf/ IMPC_Business_Plan.pdf]. A second problem, a consequence of incomplete phenotyping, is that of potential circularity where mouse models have been phenotyped with the disorder of interest to the FEA study in mind. The problem here lies in the increased likelihood that particular phenotypes thought to be relevant to this disorder will have been examined preferentially, thereby giving these genes an increased likelihood a priori of being associated with these phenotypes as compared to other genes. Thus, if a detected enrichment is largely formed from genes previously associated with the disorder, this phenotyping bias should be a concern.
Genotypic differences between the mouse model and a human patient can complicate the direct interpretation. For example, where SVs yield a hemizygous genotype in a human patient, the phenotype of mice hemizygous for the orthologues of the genes affected by the SV are of particular interest. However, rather frustratingly, the phenotype of the hemizygous knock-out mouse model is infrequently recorded, with information available for only ϳ 25% of knock-out models [Eppig et al., 2007] . This is despite the fact that the hemizygous mouse is a necessary stage in the production of the full homozygous knock-out mouse [Wolfer et al., 2002] . Secondly, SVs may affect multiple genes yielding consequences that are not well modelled by considering the simple sum of the effects of losing each affected gene individually [Girirajan et al., 2010; Yu et al., 2010] . Finally, while mouse gene knock-out models may readily relate genotypically to human deletion variants, their ability to inform on the phenotypes arising from gene copy number gains is less obvious. However, there are many microdeletion syndromes that have a reciprocal microduplication syndrome where both syndromes affect the same organ systems and have similar behavioural manifestations [Chadman et al., 2009] . Indeed, it is likely that concentrations of certain proteins have optimal levels that follow peaked distributions, such that both increased and decreased levels are deleterious [Reichelt et al., 2011] .
Importantly, if the phenotypes resulting from the loss of a set of genes of interest were uncorrelated to those resulting from their gain, then an FEA on a set of genes whose duplications gave similar phenotypes would not be expected to return any significant associations using the knock-out phenotypic resource.
While FEA can robustly associate a genic property to a set of SVs thought to underlie a particular disorder, it does not follow that those genes that contribute to that enrichment are individually robustly associated with that disorder. For example, given a highly statistically significant 3-fold enrichment of genes with a particular property, we would still expect 1 in every 3 genes that contribute to that enrichment to be sampled just by chance. Thus, each enrichment-contributing gene is identified only as a candidate gene to be taken forward for further consideration. Nonetheless, identifying the common features uniting the candidate genes can yield significant insights into the etiopathology of a genetic disorder, and genes unaffected by variants in the current cohort but that share this common genic feature might be subject to increased scrutiny in additional cohorts.
Good Practice
FEA is a powerful tool for bridging the genotype-phenotype divide. When used considerately, significant contributions can be made to the understanding of the role of structural variation in many genetic disorders. To encourage awareness and best practice, this review has discussed common flaws in current FEA applications and provided strategies for better deployment of these techniques. Most importantly, the unbiased expectation under the null hypothesis has to be demonstrated. By harnessing the rapidly growing functional genomics resources in pursuit of a better understanding of the increasing number of likely disease-causative structural variants, enrichment analysis approaches will continue to provide significant and robust biological insights.
